Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Summary

Circulating tumor DNA (ctDNA) carries tumor-specific genetic and epigenetic variations. To identify extranodal natural killer/T cell lymphoma (ENKTL)-specific methylation markers and establish a diagnostic and prognosis prediction model for ENKTL, we describe the ENKTL-specific ctDNA methylation patterns by analyzing the methylation profiles of ENKTL plasma samples. We construct a diagnostic prediction model based on ctDNA methylation markers with both high specificity and sensitivity and close relevance to tumor staging and therapeutic response. Subsequently, we built a prognostic prediction model showing excellent performance, and its predictive accuracy is significantly better than the Ann Arbor staging and prognostic index of natural killer lymphoma (PINK) risk system. Notably, we further establish a PINK-C risk grading system to select individualized treatment for patients with different prognostic risks. In conclusion, these results suggest that ctDNA methylation markers are of great value in diagnosis, monitoring, and prognosis, which might have implications for clinical decision-making of patients with ENKTL.

Graphical abstract

Highlights

•

ctDNA methylation shows great value in diagnosis, prognosis prediction of ENKTL
•

ctDNA methylation can be used as a biomarker to monitor disease progression
•

PINK-C risk assessment system could stratify patients for prognostic determinations
•

PINK-C risk assessment system might have implications for clinical decision-making

Abstract

Tian et al. identify and validate a series of ctDNA methylation markers, which can assist in the accurate diagnosis, disease monitoring, and prognosis prediction of ENKTL and may provide therapeutic optimization for early-stage patients.

Related collections

Most cited references 48

Record: found
Abstract: found
Article: not found

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Bruce D Cheson, Richard Fisher, Sally F. Barrington … (2014)

The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to revised criteria for staging and of the International Working Group Guidelines of 2007 for response. As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomography (CT) was formally incorporated into standard staging for FDG-avid lymphomas. A modification of the Ann Arbor descriptive terminology will be used for anatomic distribution of disease extent, but the suffixes A or B for symptoms will only be included for HL. A bone marrow biopsy is no longer indicated for the routine staging of HL and most diffuse large B-cell lymphomas. However, regardless of stage, general practice is to treat patients based on limited (stages I and II, nonbulky) or advanced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease based on histology and a number of prognostic factors. PET-CT will be used to assess response in FDG-avid histologies using the 5-point scale. The product of the perpendicular diameters of a single node can be used to identify progressive disease. Routine surveillance scans are discouraged. These recommendations should improve evaluation of patients with lymphoma and enhance the ability to compare outcomes of clinical trials.

0 comments Cited 1105 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Robert Camp, Marisa Dolled-Filhart, David Rimm (2004)

The ability to parse tumors into subsets based on biomarker expression has many clinical applications; however, there is no global way to visualize the best cut-points for creating such divisions. We have developed a graphical method, the X-tile plot that illustrates the presence of substantial tumor subpopulations and shows the robustness of the relationship between a biomarker and outcome by construction of a two dimensional projection of every possible subpopulation. We validate X-tile plots by examining the expression of several established prognostic markers (human epidermal growth factor receptor-2, estrogen receptor, p53 expression, patient age, tumor size, and node number) in cohorts of breast cancer patients and show how X-tile plots of each marker predict population subsets rooted in the known biology of their expression.

0 comments Cited 1092 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

The lasso method for variable selection in the Cox model.

ROBERT TIBSHIRANI (1997)

I propose a new method for variable selection and shrinkage in Cox's proportional hazards model. My proposal minimizes the log partial likelihood subject to the sum of the absolute values of the parameters being bounded by a constant. Because of the nature of this constraint, it shrinks coefficients and produces some coefficients that are exactly zero. As a result it reduces the estimation variance while providing an interpretable final model. The method is a variation of the 'lasso' proposal of Tibshirani, designed for the linear regression context. Simulations indicate that the lasso can be more accurate than stepwise selection in this setting.

0 comments Cited 1047 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Rong Tao

Wen-Yu Li

Hui-Qiang Huang

Qing-Qing Cai

Journal

Journal ID (nlm-ta): Cell Rep Med

Journal ID (iso-abbrev): Cell Rep Med

Title: Cell Reports Medicine

Publisher: Elsevier

ISSN (Electronic): 2666-3791

Publication date PMC-release: 21 February 2023

Publication date Collection: 21 February 2023

Publication date (Electronic): 21 February 2023

Volume: 4

Issue: 2

Electronic Location Identifier: 100859

Affiliations

[1 ]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China

[2 ]State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China

[3 ]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, P.R. China

[4 ]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, P.R. China

[5 ]Department of Oncology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, P. R. China

[6 ]Division of Lymphoma, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, P.R. China

[7 ]Department of Urology, Sun Yat-sen Memorial Hospital, Guangzhou, P.R. China

[8 ]Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P.R. China

[9 ]Department of Lymphoma and Hematology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, P.R. China

[10 ]Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China

[11 ]Department of Hematology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China

[12 ]Department of Clinical Laboratory, Sun Yat-sen Memorial Hospital, Guangzhou, P.R. China

[13 ]Department of Medical Examination Center, Sun Yat-sen Memorial Hospital, Guangzhou, P.R. China

[14 ]Guangdong Provincial Academy of Chinese Medical Sciences, State Key Laboratory of Dampness Syndrome of Chinese Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, P.R. China

[15 ]Lymphoma Genomic Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre Singapore, 11 Hospital Drive, 169610 Singapore, Singapore

[16 ]Department of Pathology, The First People’s Hospital of Foshan, Foshan, P.R. China

[17 ]Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, 127 Dongming Road, Zhengzhou 450008, P.R. China

[18 ]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China

[19 ]Department of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China

Author notes

[∗ ]Corresponding author rtao@ 123456shca.org.cn

[∗∗ ]Corresponding author lwy80411@ 123456163.com

[∗∗∗ ]Corresponding author huanghq@ 123456sysucc.org.cn

[∗∗∗∗ ]Corresponding author caiqq@ 123456sysucc.org.cn

[20]

These authors contributed equally

[21]

Senior author

[22]

Lead contact

Article

Publisher Item ID: S2666-3791(22)00423-2 Publisher ID: 100859

DOI: 10.1016/j.xcrm.2022.100859

PMC ID: 9975248

PubMed ID: 36812892

SO-VID: 2d1bc122-0723-450b-84ba-256ee2204ff2

License:

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

History

Date received : 7 April 2022

Date revision received : 12 July 2022

Date accepted : 18 November 2022

Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma

Read this article at

Summary

Graphical abstract

Highlights

Abstract

Related collections

Journal of Circulating Biomarkers

Most cited references 48

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

The lasso method for variable selection in the Cox model.

Author and article information

Contributors

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 136

Cited by 1

Most referenced authors 977